Clinical data
Trade names Mustophoran
AHFS/ International Drug Names
ATC code L01AD05 (WHO)
CAS Number 92118-27-9 N
PubChem (CID) 104799
DrugBank DB04106 N
ChemSpider 94600 YesY
KEGG D07255 YesY
ECHA InfoCard 100.158.792
Chemical and physical data
Formula C9H19ClN3O5P
Molar mass 315.691 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Fotemustine is a nitrosourea alkylating agent approved for use in the treatment of metastasising melanoma. A study[1] has shown that fotemustine produces improved response rates and but does not increase survival (over dacarbazine in the treatment of disseminated cutaneous melanoma. Median survival was 7.3 months with fotemustine versus 5.6 months with DTIC (P=.067). There was also toxicity prevalence in fotemustine arm. The main toxicity was grade 3 to 4 neutropenia (51% with fotemustine v 5% with DTIC) and thrombocytopenia (43% v 6%, respectively).

  1. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M (March 2004). "Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study". 22 (6): 1118–25. doi:10.1200/JCO.2004.04.165. PMID 15020614.
This article is issued from Wikipedia - version of the 8/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.